NCT03850873 2026-04-09
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
Clinical Trials
13 trialsNCT02499146 2026-02-11
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
Phase 1 Completed
NCT04728035 2024-07-26
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT06290466 2024-03-04
Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects
Ahon Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02599363 2023-11-09
A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT06098599 2023-10-24
Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer
Luye Pharma Group Ltd.
Phase 1 Completed
NCT04097756 2023-05-01
A Phase I Study of LX-039 Tablets
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 1 Completed
NCT02027376 2023-04-03
EDALINE
Spanish Breast Cancer Research Group
Phase 1 Completed
NCT02952729 2021-02-24
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
Mersana Therapeutics
Phase 1 Completed
NCT00719875 2017-03-03
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Yale University
Phase 1 Completed
NCT00452673 2015-03-24
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00106145 2015-01-30
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00328120 2010-11-17
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
AstraZeneca
Phase 1 Completed